Partnerships Keynote Session Spotlight: Disruptive Drug Development: Driving the Necessary Innovation and Change to Pioneer the Next Frontier

Leading up to Partnerships in Clinical Trials 2012, we'll profile the keynotes, tracks and themes at the 21st annual event.  For more information on Partnerships in Clinical Trials, taking place March 5-7, 2012; in Orlando, Florida, download the brochure now.  If you register and mention code XP1700Blog, you will receive a discount of 15% off the standard rate!

Every pill, every diagnostic image, every surgical procedure–medical treatment in any shape or form–stems from a single source: research. Medical innovations start with the ideas and visions of committed scientists. Successful innovations then evolve over time–not weeks or months, but years–graduating through the different stages of development: basic research, translational research, and clinical research. Recently, Temple University and Fox Chance Cancer Center in Philadelphia have become affiliated in order to better care for patients and work together to develop new and innovative ways to treat cancer patients. Physicians News Digest reports the goal of joining forces for these two centers is to "a vital source of discovery, development, and delivery of the most effective approaches to cancer prevention, diagnosis, and treatment that will give patients the best of both worlds: access to the comprehensive treatments and innovative clinical-trials available at both Temple Cancer Center and Fox Chase Cancer Center."

At the 2012 Partnerships in Clinical Trials, J. Craig Venter, Founder, Chairman, and President, J. Craig Venter Institute; Founder and CEO, Synthetic Genomics Inc., will be on hand to discuss what innovative clinical trials and research methods can do for the care of patients today.

Featured Speaker:  J. Craig Venter, Founder, Chairman, and President, J. Craig Venter Institute; Founder and CEO, Synthetic Genomics Inc.

Featured Session: Disruptive Drug Development: Driving the Necessary Innovation and Change to Pioneer the Next Frontier

About the session: Craig Venter is known as an innovative biologist who speaks his mind. Over a decade ago he lead the private effort in the quest to sequence all 3 billion base pairs in the human genome. He and his team then went on to sequences his complete diploid human genome, all 6 billion letters of DNA. This ushered in the era of personalized medicine, but many, including Dr. Venter himself, argue whether that era is truly upon us. In this provocative talk, Dr. Venter brings you inside his pioneering and unconventional approach to life sciences research and challenges you to join him in the disruption of traditional models for medical advancement. Specifically, he speaks to your biggest questions including:

• • Why has “so little” happened in the decade since the human genome was sequenced?
• • What is slowing the progress of genomic medicine?
• • What do industry and academia need to do to realize the future of personalized medicine?
• • Are we to risk adverse to create innovative breakthrough medicine?
• • How will synthetic genomics affect future medical treatments?